

Henryk Barthel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12116928/publications.pdf>

Version: 2024-02-01

158
papers

9,727
citations

34105

52
h-index

40979

93
g-index

168
all docs

168
docs citations

168
times ranked

10145
citing authors

#	ARTICLE	IF	CITATIONS
1	International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 895-904.	6.4	23
2	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
3	Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications, 2022, 13, 1362.	12.8	34
4	Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer's Disease. Biomolecules, 2022, 12, 458.	4.0	9
5	EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 632-651.	6.4	82
6	A comparison of advanced semi-quantitative amyloid PET analysis methods. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4097-4108.	6.4	4
7	PET Imaging of Cholinergic Neurotransmission in Neurodegenerative Disorders. Journal of Nuclear Medicine, 2022, 63, 33S-44S.	5.0	21
8	Future Directions in Molecular Imaging of Neurodegenerative Disorders. Journal of Nuclear Medicine, 2022, 63, 68S-74S.	5.0	7
9	Differential Diagnosis Between Alzheimer's Disease-Related Depression and Pseudo-Dementia in Depression: A New Indication for Amyloid- β Imaging?. Journal of Alzheimer's Disease, 2022, , 1-7.	2.6	2
10	Molecular Simulations Reveal Distinct Energetic and Kinetic Binding Properties of [¹⁸ F]PI-2620 on Tau Filaments from 3R/4R and 4R Tauopathies. ACS Chemical Neuroscience, 2022, 13, 2222-2234.	3.5	10
11	(+)-[18F]Flubatine as a novel $\alpha 4\beta 2$ nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with β -amyloid PET-confirmed Alzheimer's disease and healthy controls. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 731-746.	6.4	10
12	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2110-2120.	6.4	33
13	Practical setting and potential applications of interventions guided by PET/MRI. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 43-50.	0.7	2
14	Early detection of amyloid load using 18F-florbetaben PET. Alzheimer's Research and Therapy, 2021, 13, 67.	6.2	26
15	Finding our way through the labyrinth of dementia biomarkers. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2320-2324.	6.4	5
16	Cortical [¹⁸ F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes. Movement Disorders, 2021, 36, 2104-2115.	3.9	46
17	Binding characteristics of [¹⁸ F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2957-2972.	4.3	30
18	Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3872-3885.	6.4	22

#	ARTICLE	IF	CITATIONS
19	Clinical Utility of ^{125}I -Amyloid PET Imaging in People Living With HIV With Cognitive Symptoms. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 87, 826-833.	2.1	5
20	PET/MRI Delivers Multimodal Brain Signature in Alzheimer's Disease with De Novo PSEN1 Mutation. <i>Current Alzheimer Research</i> , 2021, 18, 178-184.	1.4	3
21	The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3033-3036.	6.4	6
22	Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive Supranuclear Palsy Tau Pathology With ^{18}F PI-2620. <i>Frontiers in Neurology</i> , 2021, 12, 684523.	2.4	11
23	PET Imaging of the ^{125}I -Nicotinic Acetylcholine Receptors in Alzheimer's Disease. , 2021, , 345-365.		0
24	Feasibility of short imaging protocols for ^{18}F PI-2620 tau-PET in progressive supranuclear palsy. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
25	Tau spreads across connected brain regions in progressive supranuclear palsy and corticobasal syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
26	Amyloid-PET and ^{18}F -FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , The, 2020, 19, 951-962.	10.2	254
27	Increased Immunosignals of Collagen IV and Fibronectin Indicate Ischemic Consequences for the Neurovascular Matrix Adhesion Zone in Various Animal Models and Human Stroke Tissue. <i>Frontiers in Physiology</i> , 2020, 11, 575598.	2.8	18
28	COVID-19 and the brain: impact on nuclear medicine in neurology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2487-2492.	6.4	18
29	Assessment of ^{18}F -PI-2620 as a Biomarker in Progressive Supranuclear Palsy. <i>JAMA Neurology</i> , 2020, 77, 1408.	9.0	145
30	Alzheimer's disease biomarker roadmap 2020: ^{18}F flortaucipir. <i>Alzheimer's and Dementia</i> , 2020, 16, e039550.	0.8	0
31	Alzheimer's disease biomarker roadmap 2020: Second-generation tau PET tracers. <i>Alzheimer's and Dementia</i> , 2020, 16, e039556.	0.8	1
32	Alzheimer's disease biomarker roadmap 2020: Fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2020, 16, e039557.	0.8	2
33	^{18}F -PI-2620 tau-PET in corticobasal syndrome (ActiGliA cohort). <i>Alzheimer's and Dementia</i> , 2020, 16, e041469.	0.8	1
34	Quantitative thresholds for ^{18}F -florbetaben PET for the detection of low amyloid load. <i>Alzheimer's and Dementia</i> , 2020, 16, e042933.	0.8	0
35	Alzheimer's disease biomarker roadmap 2020: Time for tau. <i>Alzheimer's and Dementia</i> , 2020, 16, e039549.	0.8	3
36	Quantitative susceptibility mapping in ^{125}I -Amyloid PET-stratified patients with dementia and healthy controls – A hybrid PET/MRI study. <i>European Journal of Radiology</i> , 2020, 131, 109243.	2.6	10

#	ARTICLE	IF	CITATIONS
37	Exploiting the Full Potential of ^{125}I -Amyloid and Tau PET Imaging for Drug Efficacy Testing. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1105-1106.	5.0	8
38	EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1885-1912.	6.4	134
39	Generalization of deep learning models for ultra-low-count amyloid PET/MRI using transfer learning. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2998-3007.	6.4	29
40	Proven validity and management impact of amyloid imaging in Alzheimer's disease "repetita juvant. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1787-1790.	6.4	1
41	Reshaping the Amyloid Buildup Curve in Alzheimer Disease? Partial-Volume Effect Correction of Longitudinal Amyloid PET Data. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1820-1824.	5.0	7
42	Hypothesis and Theory: A Pathophysiological Concept of Stroke-Induced Acute Phase Response and Increased Intestinal Permeability Leading to Secondary Brain Damage. <i>Frontiers in Neuroscience</i> , 2020, 14, 272.	2.8	9
43	Early-phase ^{18}F PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2911-2922.	6.4	36
44	A realistic phantom of the human head for PET-MRI. <i>EJNMMI Physics</i> , 2020, 7, 52.	2.7	9
45	Switching on Brain PET to Light Up Amyloid Pathology In Vivo (perspective on "In Vivo Imaging of) Tj ETQq1 1 0.784314 rgBT /Over	5.0	3
46	First Tau PET Tracer Approved: Toward Accurate In Vivo Diagnosis of Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1409-1410.	5.0	20
47	The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. <i>Journal of Nuclear Medicine</i> , 2020, 61, 263S-272S.	5.0	67
48	Current radiotracers to image neurodegenerative diseases. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 17.	3.9	28
49	Early after Administration ^{11}C PIB PET Images Correlate with Cognitive Dysfunction Measured by the CERAD Test Battery. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 65-76.	2.6	4
50	Four-repeat tauopathies. <i>Progress in Neurobiology</i> , 2019, 180, 101644.	5.7	141
51	Comparison of ^{18}F florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL approaches: Validation against histopathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 807-816.	0.8	50
52	Citalopram Improves Obsessive-Compulsive Crossword Puzzling in Frontotemporal Dementia. <i>Case Reports in Neurology</i> , 2019, 11, 94-105.	0.7	9
53	ICP003: THE CAPTAINS STUDY: STANDARDIZING VISUAL INTERPRETATION STRATEGIES FOR AMYLOID PET TRACERS. <i>Alzheimer's and Dementia</i> , 2019, 15, P14.	0.8	0
54	Lesional and perilesional tissue characterization by automated image processing in a novel gyrencephalic animal model of peracute intracerebral hemorrhage. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 2521-2535.	4.3	15

#	ARTICLE	IF	CITATIONS
55	ICâ€Pâ€161: 18Fâ€PI2620 TAUâ€PET IN PROGRESSIVE SUPRANUCLEAR PALSY: A MULTIâ€CENTER EVALUATION. Alzheimer's and Dementia, 2019, 15, P128.	0.8	3
56	Cognitive correlates of $\alpha 7$ nicotinic acetylcholine receptors in mild Alzheimerâ€™s dementia. Brain, 2018, 141, 1840-1854.	7.6	60
57	Clinical utility of FDG-PET for the clinical diagnosis in MCI. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1497-1508.	6.4	61
58	Validation of Noninvasive Tracer Kinetic Analysis of 18 F-Florbetaben PET Using a Dualâ€Time-Window Acquisition Protocol. Journal of Nuclear Medicine, 2018, 59, 1104-1110.	5.0	27
59	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
60	Dual Time-Point [18 F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 66, 1105-1116.	2.6	20
61	Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology, 2018, 91, e1390-e1401.	1.1	85
62	Impaired Neurofilament Integrity and Neuronal Morphology in Different Models of Focal Cerebral Ischemia and Human Stroke Tissue. Frontiers in Cellular Neuroscience, 2018, 12, 161.	3.7	37
63	Quantitative Susceptibility Mapping of Amyloid- β Aggregates in Alzheimerâ€™s Disease with 7T MR. Journal of Alzheimer's Disease, 2018, 64, 393-404.	2.6	39
64	Neurodegeneration Imaging. , 2018, , 99-106.		1
65	2018 SNMMI Highlights Lecture: Brain Nuclear and Molecular Imaging. Journal of Nuclear Medicine, 2018, 59, 11N-17N.	5.0	0
66	Evaluation of early-phase [18 F]-florbetaben PET acquisition in clinical routine cases. NeuroImage: Clinical, 2017, 14, 77-86.	2.7	91
67	Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 56, 441-446.	2.6	9
68	Testâ€retest measurements of dopamine D1-type receptors using simultaneous PET/MRI imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1025-1032.	6.4	50
69	Yes we can analyse amyloid images - Now What?. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 822-824.	6.4	3
70	Feasibility of in vivo 18 F-florbetaben PET/MR imaging of human carotid amyloid- β . European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1119-1128.	6.4	17
71	The need of standardization and of large clinical studies in an emerging indication of [18 F]FDG PET: the autoimmune encephalitis. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 353-357.	6.4	44
72	Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2239-2248.	6.4	15

#	ARTICLE	IF	CITATIONS
73	In vivo staging of regional amyloid deposition. <i>Neurology</i> , 2017, 89, 2031-2038.	1.1	321
74	Clinical Use and Utility of Amyloid Imaging. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1711-1717.	5.0	80
75	A new integrated dual time-point amyloid PET/MRI data analysis method. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2060-2072.	6.4	20
76	Optimized classification of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment. <i>NeuroImage: Clinical</i> , 2017, 15, 325-332.	2.7	89
77	Correlation of florbetaben PET imaging and the amyloid peptide A β 42 in cerebrospinal fluid. <i>Psychiatry Research - Neuroimaging</i> , 2017, 265, 98-101.	1.8	11
78	Cerebral Glucose Metabolism and Dopaminergic Function in Patients with Corticobasal Syndrome. <i>Journal of Neuroimaging</i> , 2017, 27, 255-261.	2.0	23
79	Damaged Neocortical Perineuronal Nets Due to Experimental Focal Cerebral Ischemia in Mice, Rats and Sheep. <i>Frontiers in Integrative Neuroscience</i> , 2017, 11, 15.	2.1	38
80	Brain PET and functional MRI: why simultaneously using hybrid PET/MR systems?. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 345-359.	0.7	21
81	Impact of Training Method on the Robustness of the Visual Assessment of ¹⁸ F-Florbetaben PET Scans: Results from a Phase-3 Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 900-906.	5.0	79
82	Combined PET/MRI. <i>Neurology</i> , 2016, 86, 1926-1927.	1.1	7
83	Evaluation of software tools for automated identification of neuroanatomical structures in quantitative ¹²⁵ I-amyloid PET imaging to diagnose Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1077-1087.	6.4	32
84	Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1700-1709.	6.4	69
85	Cerebellar Amyloid- ¹²⁵ Plaques: How Frequent Are They, and Do They Influence ¹⁸ F-Florbetaben SUV Ratios?. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1740-1745.	5.0	51
86	Role of 18F-FDG-PET imaging in the diagnosis of autoimmune encephalitis. <i>Lancet Neurology</i> , The, 2016, 15, 1009-1010.	10.2	56
87	Feasibility and acceptance of simultaneous amyloid PET/MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2236-2243.	6.4	25
88	SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1316-1322.	5.0	161
89	Fully automated calculation of image-derived input function in simultaneous PET/MRI in a sheep model. <i>EJNMMI Physics</i> , 2016, 3, 2.	2.7	20
90	Academic-industry Collaborations in Translational Stroke Research. <i>Translational Stroke Research</i> , 2016, 7, 343-353.	4.2	12

#	ARTICLE	IF	CITATIONS
91	Partial-Volume Effect Correction Improves Quantitative Analysis of ¹⁸ F-Florbetaben ¹²⁵ I-Amyloid PET Scans. <i>Journal of Nuclear Medicine</i> , 2016, 57, 198-203.	5.0	58
92	Focal Cerebral Ischemia by Permanent Middle Cerebral Artery Occlusion in Sheep: Surgical Technique, Clinical Imaging, and Histopathological Results. <i>NeuroMethods</i> , 2016, , 195-225.	0.3	6
93	Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 425-432.	2.6	16
94	Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 539-543.	2.6	7
95	In Vivo Correlation of Glucose Metabolism, Cell Density and Microcirculatory Parameters in Patients with Head and Neck Cancer: Initial Results Using Simultaneous PET/MRI. <i>PLoS ONE</i> , 2015, 10, e0134749.	2.5	27
96	Simultaneous PET/Mri in Stroke: A Case Series. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1421-1425.	4.3	57
97	The role of positron emission tomography imaging in understanding Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 395-406.	2.8	27
98	PET/MR in Dementia and Other Neurodegenerative Diseases. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 224-233.	4.6	101
99	Beta-amyloid imaging with florbetaben. <i>Clinical and Translational Imaging</i> , 2015, 3, 13-26.	2.1	120
100	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	7.4	1,166
101	Prevalence of Amyloid PET Positivity in Dementia Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1939.	7.4	501
102	Dissociation of amyloid biomarkers in PET and CSF in Alzheimer's disease: a case report. <i>BMC Neurology</i> , 2015, 15, 152.	1.8	4
103	Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection. <i>Lancet Neurology</i> , The, 2015, 14, 1037-1053.	10.2	233
104	Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study. <i>Alzheimer's and Dementia</i> , 2015, 11, 964-974.	0.8	400
105	First-in-human PET quantification study of cerebral ¹²⁵ I-α-BTX nicotinic acetylcholine receptors using the novel specific radioligand (α ¹²⁵ I)-[18F]Flubatine. <i>NeuroImage</i> , 2015, 118, 199-208.	4.2	49
106	Ethnic comparison of pharmacokinetics of 18F-florbetaben, a PET tracer for beta-amyloid imaging, in healthy Caucasian and Japanese subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 89-96.	6.4	8
107	Potential Pediatric Applications of PET/MR. <i>Journal of Nuclear Medicine</i> , 2014, 55, 32S-39S.	5.0	57
108	Integrated PET/MRI for planning navigated biopsies in pediatric brain tumors. <i>Child's Nervous System</i> , 2014, 30, 1399-1403.	1.1	45

#	ARTICLE	IF	CITATIONS
109	Potential Clinical Applications of PET/MR Imaging in Neurodegenerative Diseases. Journal of Nuclear Medicine, 2014, 55, 47S-55S.	5.0	62
110	Combined PET/MR: Where Are We Now? Summary Report of the Second International Workshop on PET/MR Imaging April 8-12, 2013, Tubingen, Germany. Molecular Imaging and Biology, 2014, 16, 295-310.	2.6	38
111	Preclinical Aspects of Nicotinic Acetylcholine Receptor Imaging. , 2014, , 465-512.		4
112	Cerebral Blood Flow Measurement with Oxygen-15 Water Positron Emission Tomography. , 2014, , 103-124.		1
113	PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner. Pediatric Radiology, 2013, 43, 860-875.	2.0	136
114	Influence of scan duration on the accuracy of 125 I-amyloid PET with florbetaben in patients with Alzheimer's disease and healthy volunteers. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 238-244.	6.4	28
115	Meta-analysis based SVM classification enables accurate detection of Alzheimer's disease across different clinical centers using FDG-PET and MRI. Psychiatry Research - Neuroimaging, 2013, 212, 230-236.	1.8	107
116	Neural correlates of the DemTect in Alzheimer's disease and frontotemporal lobar degeneration - A combined MRI & FDG-PET study. NeuroImage: Clinical, 2013, 2, 746-758.	2.7	18
117	Physical and organizational provision for installation, regulatory requirements and implementation of a simultaneous hybrid PET/MR-imaging system in an integrated research and clinical setting. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2013, 26, 159-171.	2.0	26
118	PET Quantification of 18 F-Florbetaben Binding to 125 I-Amyloid Deposits in Human Brains. Journal of Nuclear Medicine, 2013, 54, 723-731.	5.0	101
119	Dissociating Memory Networks in Early Alzheimer's Disease and Frontotemporal Lobar Degeneration - A Combined Study of Hypometabolism and Atrophy. PLoS ONE, 2013, 8, e55251.	2.5	59
120	Reference Cluster Normalization Improves Detection of Frontotemporal Lobar Degeneration by Means of FDG-PET. PLoS ONE, 2013, 8, e55415.	2.5	25
121	Inhalation of Nitric Oxide Prevents Ischemic Brain Damage in Experimental Stroke by Selective Dilatation of Collateral Arterioles. Circulation Research, 2012, 110, 727-738.	4.5	163
122	Executive deficits are related to the inferior frontal junction in early dementia. Brain, 2012, 135, 201-215.	7.6	87
123	Perspectives for Multimodal Neurochemical and Imaging Biomarkers in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, S329-S347.	2.6	21
124	PET Imaging of Dementia. , 2012, , 244-250.		2
125	Florbetaben to Trace Amyloid- 125 I in the Alzheimer Brain by Means of PET. Journal of Alzheimer's Disease, 2011, 26, 117-121.	2.6	52
126	Combined Evaluation of FDG-PET and MRI Improves Detection and Differentiation of Dementia. PLoS ONE, 2011, 6, e18111.	2.5	129

#	ARTICLE	IF	CITATIONS
127	Dissociating behavioral disorders in early dementiaâ€”An FDG-PET study. <i>Psychiatry Research - Neuroimaging</i> , 2011, 194, 235-244.	1.8	61
128	Cerebral amyloid- β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. <i>Lancet Neurology</i> , The, 2011, 10, 424-435.	10.2	491
129	Decreased cerebral β 2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimerâ€™s disease assessed with positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 515-525.	6.4	109
130	Individualized quantification of brain β -amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimerâ€™s disease and healthy controls. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1702-1714.	6.4	91
131	Executive and behavioral deficits share common neural substrates in frontotemporal lobar degeneration â€” A pilot FDG-PET study. <i>Psychiatry Research - Neuroimaging</i> , 2010, 182, 274-280.	1.8	33
132	Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies. <i>NeuroImage</i> , 2010, 49, 1490-1495.	4.2	118
133	Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder. <i>Psychiatry Research - Neuroimaging</i> , 2009, 171, 120-128.	1.8	61
134	Monoamine transporter availability in Parkinsonâ€™s disease patients with or without depression. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 428-435.	6.4	72
135	Reduced β 2*â€”Nicotinic Acetylcholine Receptor Binding and Its Relationship to Mild Cognitive and Depressive Symptoms in Parkinson Disease. <i>Archives of General Psychiatry</i> , 2009, 66, 866.	12.3	140
136	Permanent Middle Cerebral Artery Occlusion in Sheep: A Novel Large Animal Model of Focal Cerebral Ischemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 1951-1964.	4.3	88
137	Serotonin Transporter Imaging with [¹²³ I] β -CIT SPECT before and after One Year of Citalopram Treatment of Obsessive-Compulsive Disorder. <i>Neuropsychobiology</i> , 2006, 53, 40-45.	1.9	28
138	Redistribution of Nucleoside Transporters to the Cell Membrane Provides a Novel Approach for Imaging Thymidylate Synthase Inhibition by Positron Emission Tomography. <i>Cancer Research</i> , 2006, 66, 8558-8564.	0.9	87
139	The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 257-263.	6.4	120
140	Serotonin and dopamine transporter imaging in patients with obsessiveâ€”compulsive disorder. <i>Psychiatry Research - Neuroimaging</i> , 2005, 140, 63-72.	1.8	132
141	Nicotinic acetylcholine receptors in patients with Parkinson's disease and Alzheimer's disease: Specific binding of 2-[18F]F-A-85380 in the cerebral white matter as demonstrated by PET and comparison with diffusion tensor MRI (DTI). <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S584-S584.	4.3	0
142	Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2004, 28, 547-563.	6.1	59
143	Small-animal imaging of tumour proliferation with PET. <i>Lancet Oncology</i> , The, 2004, 5, 100.	10.7	6
144	Is correction for age necessary in neuroimaging studies of the central serotonin transporter?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 427-430.	6.4	49

#	ARTICLE	IF	CITATIONS
145	Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease. <i>American Journal of Neuroradiology</i> , 2003, 24, 234-8.	2.4	51
146	3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. <i>Cancer Research</i> , 2003, 63, 3791-8.	0.9	201
147	Correlation between automated writing movements and striatal dopaminergic innervation in patients with Wilson's disease. <i>Journal of Neurology</i> , 2002, 249, 1082-1087.	3.6	19
148	Prospective Value of Perfusion and X-Ray Attenuation Imaging With Single-Photon Emission and Transmission Computed Tomography in Acute Cerebral Ischemia. <i>Stroke</i> , 2001, 32, 1588-1597.	2.0	21
149	In Vivo Evidence for Differential Association of Striatal Dopamine and Midbrain Serotonin Systems With Neuropsychiatric Symptoms in Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001, 13, 222-228.	1.8	76
150	Differential alteration of the nigrostriatal dopaminergic system in Wilson's disease investigated with [123I]ÅŸ-CIT and high-resolution SPET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 1656-1663.	2.1	32
151	Potential of Rheopheresis for the Treatment of Acute Ischemic Stroke When Initiated Between 6 and 12â€fHours. <i>Therapeutic Apheresis and Dialysis</i> , 2000, 4, 358-362.	0.6	2
152	Reperfusion and Metabolic Recovery of Brain Tissue and Clinical Outcome After Ischemic Stroke and Thrombolytic Therapy. <i>Stroke</i> , 2000, 31, 1545-1551.	2.0	39
153	Changes in myocardial perfusion after catheter-based percutaneous laser revascularisation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1292-1299.	2.1	5
154	Extracorporeal Rheopheresis in the Treatment of Acute Ischemic Stroke. <i>Stroke</i> , 1999, 30, 787-792.	2.0	15
155	Differentiation between Transient Ischemic Attack and Ischemic Stroke within the First Six Hours after Onset of Symptoms by Using ^{99m} Tc-ECD-SPECT. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1998, 18, 921-929.	4.3	50
156	^{99m} Technetium-Ethyl-Cysteinate-Dimer Single-Photon Emission CT Can Predict Fatal Ischemic Brain Edema. <i>Stroke</i> , 1998, 29, 2556-2562.	2.0	110
157	Age-specific cerebral perfusion in 4- to 15-year-old children: a high-resolution brain SPET study using ^{99m} Tc-ECD. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 1245-1252.	6.4	26
158	Changes in local cerebral blood flow by neuroactivation and vasoactivation in patients with impaired cognitive function. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 878-888.	2.1	21